Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danish healthcare firm Novo Nordisk is planning to set up new obesity research unit in Seattle, Washington, US, in order to increase its focus on treatment of obesity.
Subscribe to our email newsletter
The new unit will be aimed at identifying new approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets.
Initially, around ten people will be employed at the Novo Nordisk Obesity Research Unit and will be supported by the current obesity research and corporate functions.
The new unit is scheduled to be fully operational by the end of 2016 and is expected to employ around 60 employees.
Currently, around 300 employees across the world are working within Novo Nordisk’s obesity research and development.
Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen said, "Our ambition is to drive scientific progress in the obesity disease area and through this identify and develop new treatment options for people with obesity."
The company’s new Obesity Research Unit will be lead by Dr Kevin Grove, an expert in endocrinology specialising in obesity and health-related quality of life.
Grove said, "I’m looking forward to leading the Novo Nordisk Obesity Research Unit in Seattle and gather a team of preeminent researchers within the obesity and endocrinology field."